TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial

Study identifier:SH-AHM-0030

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double-blind, Placebo-controlled, Multicenter, Long-term Trial of Preventing Hypertension using Candesartan Cilexetil 16 mg in Patients with High Normal Blood Pressure (TROPHY)

Medical condition

hypertension

Phase

Phase 3

Healthy volunteers

Study drug

ATACAND

Sex

All

Actual Enrollment

1000

Study type

Interventional

Age

30 Years - 65 Years

Date

Study Start Date: 01 Jul 1998

Primary Completion Date: 01 Oct 2005

Study Completion Date: 01 Oct 2005

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: None
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Aug 2011 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

Trial Results Summaries
Available here

Contacts

Contact

TROPHY Coordinating Center

1- 800-TROPHY 0

Investigators

Principal Investigator

Atacand Medical Science Director

AstraZeneca